English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/126491
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Exportar a otros formatos:

Title

Oligonucleotide delivery: A patent review (2010-2013)

AuthorsEritja Casadellà, Ramón ; Grijalvo, Santiago ; Aviñó, Anna
KeywordsAntisense
Aptamers
Cell penetration peptides
Drug delivery
Liposomes
Oligonucleotides
Nanoparticles
Polymers
RNA interference
Small interference RNA
Issue DateJul-2014
PublisherInforma Healthcare
CitationExpert Opinion on Therapeutic Patents
AbstractIntroduction: The use of aptamers, antisense technology and RNA interference has allowed nucleic acids to be considered as promising alternatives to classical drugs. However, nucleic acids face several obstacles in the creation of effective nucleic acid drugs. The development of these approaches has strengthened the pipeline with an increasing number of these therapies in clinical trials.Areas covered: This review covers research and patent literature from the last three years, focusing on the development of safe and effective non-viral drug delivery systems for the treatment of diseases such as cancer or genetic disorders by using oligonucleotides.Expert opinion: The therapeutic applications of oligonucleotides have overcome multiple obstacles, especially in biodistribution and cellular internalization. Cationic lipids are the most used vehicles for the preparation of novel formulations. Combinatorial libraries of these compounds and the use of solid lipid nanoparticles carrying these synthetic cationic lipids (cholesterol and PEG) have enhanced cellular uptake and biocompatibility of nucleic acids. Besides this extensive use, synthesis of oligonucleotides covalently linked to lipids has also emerged as a promising alternative to formulations. The use of peptides alone or in combination with lipids is an expanding field for oligonucleotide delivery. Polymeric platforms are also good candidates as they showed improved cellular uptake, biodegradability, biocompatibility and the possibility of incorporating several components, such as ligands for receptor-mediated endocytosis and molecules, to facilitate endosomal escape. Finally, nanomaterials may also play an important role in the future. The last developments showed improvement in in vivo efficacy, thus gaining a foothold in therapeutics.
Publisher version (URL)DOI: 10.1517/13543776.2014.915944
URIhttp://hdl.handle.net/10261/126491
DOIhttp://dx.doi.org/10.1517/13543776.2014.915944
Appears in Collections:(IQAC) Artículos
Files in This Item:
File Description SizeFormat 
expertOpinion2014.pdfArtículo principal708,29 kBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.